Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety Study of Topical Bromfenac Ophthalmic Solution vs. Placebo for Treatment of Ocular Inflammation and Pain Associated With Cataract Surgery.

Next Previous
Trial Profile

Efficacy and Safety Study of Topical Bromfenac Ophthalmic Solution vs. Placebo for Treatment of Ocular Inflammation and Pain Associated With Cataract Surgery.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Feb 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bromfenac (Primary)
  • Indications Ocular inflammation; Ocular pain; Postoperative pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Bausch & Lomb

Most Recent Events

  • 08 Jun 2011 Actual end date changed from 9 Feb 2007 to Mar 2007 as reported by ClinicalTrials.gov.
  • 12 Nov 2007 Results, including the primary endpoint, from these two trials were presented at the 2007 Annual Meeting of the American Academy of Opthalmology, held in New Orleans, Louisiana, USA.
  • 12 Nov 2007 Status changed from in progress to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top